Azitra, Inc. completed a $10 million public offering on July 25, 2024, issuing 6,665,000 common shares and Class A warrants for 13,330,000 shares at $1.50 per unit. The Class A warrants, exercisable immediately, expire in 5 years with an initial $1.50 exercise price, subject to potential downward adjustment after 30 days.Maxim Group LLC acted as the exclusive placement agent, receiving a 7% cash fee and expense reimbursement up to $100,000. Azitra also issued warrants to Maxim's designees for 266,600 shares at $1.875 per share, exercisable from January 23, 2025 to July 23, 2029.Net proceeds of approximately $8.95 million will be used for general corporate purposes and working capital. The offering was made pursuant to an effective S-1 registration statement. Azitra, a clinical-stage biopharmaceutical company, focuses on developing innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products.

Azitra, Inc. completed a $10 million public offering on July 25, 2024, issuing 6,665,000 common shares and Class A warrants for 13,330,000 shares at $1.50 per unit. The Class A warrants, exercisable immediately, expire in 5 years with an initial $1.50 exercise price, subject to potential downward adjustment after 30 days.Maxim Group LLC acted as the exclusive placement agent, receiving a 7% cash fee and expense reimbursement up to $100,000. Azitra also issued warrants to Maxim's designees for 266,600 shares at $1.875 per share, exercisable from January 23, 2025 to July 23, 2029.Net proceeds of approximately $8.95 million will be used for general corporate purposes and working capital. The offering was made pursuant to an effective S-1 registration statement. Azitra, a clinical-stage biopharmaceutical company, focuses on developing innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products.